Neuroinflammation and white-matter changes in corticobasal syndrome

Neuroinflammation, white matter integrity, AD biomarkers and pathology in corticobasal syndrome

NIH-funded research Mayo Clinic Rochester · NIH-11309163

This project uses advanced brain scans and blood tests to look for inflammation and white-matter changes in people with corticobasal syndrome and to see which cases are linked to Alzheimer’s-related changes.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionMayo Clinic Rochester NIH-funded
Lab location1 site (Rochester, United States)
Project IDNIH-11309163 on NIH RePORTER

What this research studies

If you join, you'll have clinical testing, an advanced MRI (NODDI) that measures white-matter microstructure, PET scans for brain inflammation (ER176) and for amyloid and tau, plus a blood draw to check inflammatory markers. The study will prospectively recruit 80 people with corticobasal syndrome and classify participants using amyloid and tau PET into those with Alzheimer-type biomarkers and those with 4-repeat tau pathology. Researchers will compare where inflammation and white-matter damage occur in the brain and relate those patterns to the molecular biomarker results. The team aims to link biological mechanisms to the different underlying pathologies of CBS to inform future targeted approaches.

Who could benefit from this research

Good fit: People diagnosed with corticobasal syndrome who can travel to Mayo Clinic and tolerate PET/MRI scans and blood draws are ideal candidates.

Not a fit: People without corticobasal syndrome or those who cannot undergo PET/MRI or blood draws are unlikely to benefit from participating.

Why it matters

Potential benefit: Could help doctors distinguish CBS caused by Alzheimer-related changes from other tauopathies and point toward inflammation-targeted treatments for specific patient groups.

How similar studies have performed: Prior PET and blood-biomarker work has linked neuroinflammation to Alzheimer’s and some tauopathies, but using ER176 PET together with NODDI MRI and fluid markers specifically in CBS is relatively new.

Where this research is happening

Rochester, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementia
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.